Abbott, the parent company of Madison’s Exact Sciences, will present new evidence of the effectiveness of its cancer screenings products during the American Society of Clinical Oncology annual meeting, held May 29 – June 2 in Chicago.
Based on data from its recent study, Abbott will showcase the breadth of its integrated cancer diagnostics product portfolio and demonstrate how its tests support critical decision points across the cancer care continuum — from identifying risk to detecting disease earlier to guiding treatment and monitoring for recurrence.
Jake Orville, senior vice president of Abbott’s cancer diagnostics business, said in a statement that the data indicate a shift in oncology toward more precise detection, improved personalized care and clearer treatment decisions without adding patient burden or stress.
“Cancer care is at an inflection point, and diagnostics are playing an increasingly central role in how the disease is detected, treated and managed,” Orville said. “By combining tools used for screening, early detection, treatment guidance and recurrence monitoring, we’re helping clinicians make more informed decisions at every stage of cancer care, from risk through remission.”
Among the findings is new Molecular Residual Disease (MRD) test data that demonstrates enhanced sensitivity in early triple-negative breast cancer. This type of cancer is a fast-growing, aggressive cancer that tests negative for estrogen, progesterone and HER2 receptors, which means that common hormone or targeted therapies are ineffective.
Since triple-negative breast cancer tends to grow faster and is more likely to recur than other breast cancer subtypes, early detection and prompt and aggressive treatment are critical.
Abbott also will present data about the development of an endometrial cancer test from a vaginal swab. There is no routine screening for endometrial cancer, the most common type of gynecologic cancer, for women who do not have symptoms such as abnormal bleeding. The test is being developed to provide earlier diagnosis.
Endometrial cancer is commonly known as uterine cancer. A Pap test or Pap smear is a primary screening method used to detect cervical cancer.
